Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases

Randall (Randy) Woltjer, Dejan Milatovic

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The chapter describes the rationale for therapies in Alzheimer's disease (AD), aspects of their application to clinical disease, and what is learned from the effects of the drugs in neurodegenerative disease. Effective preventive and therapeutic strategies for AD and other age-related neurodegenerative diseases are the most pressing need in modern clinical neurological practice. The multifactorial nature of the etiology of sporadic AD seems to imply a likelihood that the most effective treatment strategies will target several or many of these processes. Indeed, many models of the progression of AD invoke self-reinforcing cycles of cerebral damage that may be checked in part at any one of a number of steps, but that may be best approached by therapeutic strategies that target multiple aspects of disease pathogenesis. Definitive experimental evidence of a role of ACh in the pathogenesis of human neurodegenerative disease may prove elusive, and perhaps unambiguously manifest only in the context of cotreatments with AChEIs and agents that target other aspects of disease. The symptomatic effects of AChEIs alone dictate that they will remain important treatments for AD.

Original languageEnglish (US)
Title of host publicationToxicology of Organophosphate & Carbamate Compounds
PublisherElsevier Inc.
Pages25-33
Number of pages9
ISBN (Print)9780120885237
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Neurodegenerative diseases
Cholinesterase Inhibitors
Therapeutic Uses
Neurodegenerative Diseases
Alzheimer Disease
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Woltjer, R. R., & Milatovic, D. (2006). Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases. In Toxicology of Organophosphate & Carbamate Compounds (pp. 25-33). Elsevier Inc.. https://doi.org/10.1016/B978-012088523-7/50004-1

Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases. / Woltjer, Randall (Randy); Milatovic, Dejan.

Toxicology of Organophosphate & Carbamate Compounds. Elsevier Inc., 2006. p. 25-33.

Research output: Chapter in Book/Report/Conference proceedingChapter

Woltjer, RR & Milatovic, D 2006, Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases. in Toxicology of Organophosphate & Carbamate Compounds. Elsevier Inc., pp. 25-33. https://doi.org/10.1016/B978-012088523-7/50004-1
Woltjer RR, Milatovic D. Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases. In Toxicology of Organophosphate & Carbamate Compounds. Elsevier Inc. 2006. p. 25-33 https://doi.org/10.1016/B978-012088523-7/50004-1
Woltjer, Randall (Randy) ; Milatovic, Dejan. / Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases. Toxicology of Organophosphate & Carbamate Compounds. Elsevier Inc., 2006. pp. 25-33
@inbook{0f6d6681d00d4df9824b07f09de75db4,
title = "Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases",
abstract = "The chapter describes the rationale for therapies in Alzheimer's disease (AD), aspects of their application to clinical disease, and what is learned from the effects of the drugs in neurodegenerative disease. Effective preventive and therapeutic strategies for AD and other age-related neurodegenerative diseases are the most pressing need in modern clinical neurological practice. The multifactorial nature of the etiology of sporadic AD seems to imply a likelihood that the most effective treatment strategies will target several or many of these processes. Indeed, many models of the progression of AD invoke self-reinforcing cycles of cerebral damage that may be checked in part at any one of a number of steps, but that may be best approached by therapeutic strategies that target multiple aspects of disease pathogenesis. Definitive experimental evidence of a role of ACh in the pathogenesis of human neurodegenerative disease may prove elusive, and perhaps unambiguously manifest only in the context of cotreatments with AChEIs and agents that target other aspects of disease. The symptomatic effects of AChEIs alone dictate that they will remain important treatments for AD.",
author = "Woltjer, {Randall (Randy)} and Dejan Milatovic",
year = "2006",
doi = "10.1016/B978-012088523-7/50004-1",
language = "English (US)",
isbn = "9780120885237",
pages = "25--33",
booktitle = "Toxicology of Organophosphate & Carbamate Compounds",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Therapeutic uses of cholinesterase inhibitors in neurodegenerative diseases

AU - Woltjer, Randall (Randy)

AU - Milatovic, Dejan

PY - 2006

Y1 - 2006

N2 - The chapter describes the rationale for therapies in Alzheimer's disease (AD), aspects of their application to clinical disease, and what is learned from the effects of the drugs in neurodegenerative disease. Effective preventive and therapeutic strategies for AD and other age-related neurodegenerative diseases are the most pressing need in modern clinical neurological practice. The multifactorial nature of the etiology of sporadic AD seems to imply a likelihood that the most effective treatment strategies will target several or many of these processes. Indeed, many models of the progression of AD invoke self-reinforcing cycles of cerebral damage that may be checked in part at any one of a number of steps, but that may be best approached by therapeutic strategies that target multiple aspects of disease pathogenesis. Definitive experimental evidence of a role of ACh in the pathogenesis of human neurodegenerative disease may prove elusive, and perhaps unambiguously manifest only in the context of cotreatments with AChEIs and agents that target other aspects of disease. The symptomatic effects of AChEIs alone dictate that they will remain important treatments for AD.

AB - The chapter describes the rationale for therapies in Alzheimer's disease (AD), aspects of their application to clinical disease, and what is learned from the effects of the drugs in neurodegenerative disease. Effective preventive and therapeutic strategies for AD and other age-related neurodegenerative diseases are the most pressing need in modern clinical neurological practice. The multifactorial nature of the etiology of sporadic AD seems to imply a likelihood that the most effective treatment strategies will target several or many of these processes. Indeed, many models of the progression of AD invoke self-reinforcing cycles of cerebral damage that may be checked in part at any one of a number of steps, but that may be best approached by therapeutic strategies that target multiple aspects of disease pathogenesis. Definitive experimental evidence of a role of ACh in the pathogenesis of human neurodegenerative disease may prove elusive, and perhaps unambiguously manifest only in the context of cotreatments with AChEIs and agents that target other aspects of disease. The symptomatic effects of AChEIs alone dictate that they will remain important treatments for AD.

UR - http://www.scopus.com/inward/record.url?scp=34548459381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548459381&partnerID=8YFLogxK

U2 - 10.1016/B978-012088523-7/50004-1

DO - 10.1016/B978-012088523-7/50004-1

M3 - Chapter

SN - 9780120885237

SP - 25

EP - 33

BT - Toxicology of Organophosphate & Carbamate Compounds

PB - Elsevier Inc.

ER -